Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Summary

Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase II trial to study the effectiveness of trastuzumab in treating patients who have stage III, stage IV, or recurrent endometrial cancer.

Timeline

Start

2000-09-18

Primary completion

2007-09-04

Completion

2010-01-31

Drugs

Indications